We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

152 hedge funds and large institutions have $206M invested in Vanda Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 47 increasing their positions, 52 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

501% more call options, than puts

Call options by funds: $1.57M | Put options by funds: $261K

25% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 20

3% more funds holding

Funds holding: 148 → 152 (+4)

0.65% more ownership

Funds ownership: 74.8% → 75.45% (+0.65%)

10% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 52

16% less capital invested

Capital invested by funds: $246M → $206M (-$39.7M)

Holders
152
Holders Change
+4
Holders Change %
+2.7%
% of All Funds
2.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
47
Reduced
52
Closed
20
Calls
$1.57M
Puts
$261K
Net Calls
+$1.31M
Net Calls Change
+$2.12M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.45M
2
Goldman Sachs
Goldman Sachs
New York
+$2.16M
3
Millennium Management
Millennium Management
New York
+$2.05M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.33M
5
TCM
Tang Capital Management
California
+$1.07M

Top Sellers

Rank Fund Capital Flow
1
N
Nuveen
North Carolina
-$1.99M
2
KAM
Krensavage Asset Management
New York
-$1.33M
3
PIM
Profit Investment Management
Maryland
-$1.29M
4
BCM
BML Capital Management
Indiana
-$910K
5
OAC
OMERS Administration Corp
Ontario, Canada
-$788K
Name Holding Trade Value Shares
Change 		Change in
Stake
American Century Companies
26
American Century Companies
Missouri
$1.38M +$130K +24,226 +9%
Los Angeles Capital Management
27
Los Angeles Capital Management
California
$1.3M -$258K -48,080 -15%
Ameriprise
28
Ameriprise
Minnesota
$1.13M -$10.7K -2,005 -0.8%
BCM
29
BML Capital Management
Indiana
$1.07M -$910K -169,780 -43%
EF
30
Empowered Funds
Pennsylvania
$1.07M +$61.8K +11,524 +5%
Invesco
31
Invesco
Georgia
$1.06M -$412K -76,776 -25%
KCM
32
Kennedy Capital Management
Missouri
$1.06M -$15.4K -2,869 -1%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$963K -$283K -52,718 -20%
TI
34
Trexquant Investment
Connecticut
$959K +$711K +132,613 +185%
MAM
35
Monaco Asset Management
Monaco
$954K +$56.3K +10,500 +5%
Massachusetts Financial Services
36
Massachusetts Financial Services
Massachusetts
$864K +$987K +184,181 New
COPPSERS
37
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$821K – – –
State of Wisconsin Investment Board
38
State of Wisconsin Investment Board
Wisconsin
$816K +$398K +74,200 +74%
JP Morgan Chase
39
JP Morgan Chase
New York
$754K +$119K +22,249 +16%
N
40
Nuveen
North Carolina
$726K -$1.99M -372,073 -71%
Barclays
41
Barclays
United Kingdom
$724K +$465K +86,677 +128%
Allspring Global Investments
42
Allspring Global Investments
North Carolina
$711K +$901 +168 +0.1%
Fidelity Investments
43
Fidelity Investments
Massachusetts
$702K +$165K +30,802 +26%
Citadel Advisors
44
Citadel Advisors
Florida
$668K -$26.8K -5,001 -3%
Two Sigma Advisers
45
Two Sigma Advisers
New York
$659K -$394K -73,500 -34%
ECM
46
ExodusPoint Capital Management
New York
$589K +$674K +125,650 New
Norges Bank
47
Norges Bank
Norway
$539K – – –
AllianceBernstein
48
AllianceBernstein
Tennessee
$526K -$25.9K -4,830 -4%
Ohio Public Employees Retirement System (OPERS)
49
Ohio Public Employees Retirement System (OPERS)
Ohio
$498K -$21.4K -4,000 -4%
Lazard Asset Management
50
Lazard Asset Management
New York
$483K +$528K +98,516 +2,144%
1
2
3 4 5

VNDA Hedge Fund Activity: Q3 2024 in Review

152 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2024, worth a combined $206M — down 16% from $246M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new VNDA positions and 20 closed out — a net gain of 5 holders — while 47 added to existing stakes and 52 trimmed.

The largest buyer was BlackRock, adding an estimated $2.45M. The largest seller was Nuveen, cutting an estimated $1.99M.

  • 152 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2024, up from 148 in Q2 2024.
  • Funds reported $206M of Vanda Pharmaceuticals stock for Q3 2024, down 16% quarter-over-quarter.
  • 25 funds opened new Vanda Pharmaceuticals positions in Q3 2024 and 20 closed out, a net change of +5 holders.
  • The largest Vanda Pharmaceuticals buyer in Q3 2024 was BlackRock, an estimated $2.45M added.
  • The largest Vanda Pharmaceuticals seller in Q3 2024 was Nuveen, an estimated $1.99M sold.

Based on aggregated 13F filings for Q3 2024.